Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David F McDermott

Showing results (61-70 of 227) with videos related to

Pageof 23
Sort By:
The Oncologist|December 28, 2022
Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3Luis Meza, David F McDermott, Bernard Escudier, et al.
JCO Oncology Practice|July 14, 2025
Long-Term Performance of Prognostic Models for Advanced Renal Cell Carcinoma in the Era of Improved Survival With Immune Checkpoint InhibitorsCharlene M Mantia, Opeyemi A Jegede, David F McDermott, et al.
Clinical Genitourinary Cancer|May 19, 2021
A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell CarcinomaSimon Chowdhury, Jeffery R Infante, Robert Hawkins, et al.
Clinical Genitourinary Cancer|September 12, 2022
Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney CancerZeynep B Zengin, Sumanta K Pal, David F McDermott, et al.
The Journal of Urology|November 16, 2010
The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapyToni K Choueiri, Wanling Xie, Christian Kollmannsberger, et al.
Journal for Immunotherapy of Cancer|August 4, 2025
Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trialEmiliano Calvo, Valentina Boni, Olivier Dumas, et al.
The Lancet. Oncology|December 8, 2019
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label studyBrian I Rini, Sumanta K Pal, Bernard J Escudier, et al.
Pediatric Dermatology|August 27, 2009
Autosomal dominant epidermodysplasia verruciformis lacking a known EVER1 or EVER2 mutationDavid F McDermott, Bryan Gammon, Peter J Snijders, et al.
JAMA|November 5, 2014
Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trialF Stephen Hodi, Sandra Lee, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2015
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804)Keith T Flaherty, Judith B Manola, Michael Pins, et al.
Pageof 23

Showing results (61-70 of 227) with videos related to

Sort By:
Pageof 23
The Oncologist|December 28, 2022
Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3Luis Meza, David F McDermott, Bernard Escudier, et al.
JCO Oncology Practice|July 14, 2025
Long-Term Performance of Prognostic Models for Advanced Renal Cell Carcinoma in the Era of Improved Survival With Immune Checkpoint InhibitorsCharlene M Mantia, Opeyemi A Jegede, David F McDermott, et al.
Clinical Genitourinary Cancer|May 19, 2021
A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell CarcinomaSimon Chowdhury, Jeffery R Infante, Robert Hawkins, et al.
Clinical Genitourinary Cancer|September 12, 2022
Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney CancerZeynep B Zengin, Sumanta K Pal, David F McDermott, et al.
The Journal of Urology|November 16, 2010
The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapyToni K Choueiri, Wanling Xie, Christian Kollmannsberger, et al.
Journal for Immunotherapy of Cancer|August 4, 2025
Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trialEmiliano Calvo, Valentina Boni, Olivier Dumas, et al.
The Lancet. Oncology|December 8, 2019
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label studyBrian I Rini, Sumanta K Pal, Bernard J Escudier, et al.
Pediatric Dermatology|August 27, 2009
Autosomal dominant epidermodysplasia verruciformis lacking a known EVER1 or EVER2 mutationDavid F McDermott, Bryan Gammon, Peter J Snijders, et al.
JAMA|November 5, 2014
Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trialF Stephen Hodi, Sandra Lee, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2015
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804)Keith T Flaherty, Judith B Manola, Michael Pins, et al.
Pageof 23